Canine and human prostates were treated with high intensity focused ultrasound (HIFU) using a transrectal probe. Near the beam focus, temperatures were shown t o be greater than 60" C, while periprostatic tissue temperatures increased 5 3" C; rectal wall temperatures did not rise more than 5 ' C over the baseline. In 15 patients with benign prostatic hyperplasia (BPH), no major complications resulted from HlFU treatment, and statistically significant improvements in peak and average flow rates were observed at both 90 and 180 days post-treatment.
INTRODUCTION
Noninvasive medical procedures are currently in great demand, both from patients seeking alternatives to surgery, as well as from hospitals attempting to improve cost-effectiveness of treatment (which is highly dependent upon the length of hospitalization and any resultant morbidity or mortality). As well as being the safest imaging modality, ultrasound can also be focused deep within the body to destroy small regions of tissue without causing damage to the intervening layers[l I. If the challenges to endocavity and extracorporeal applications can be met, HlFU may achieve the goal of providing a safe non-invasive outpatient alternative t o a variety of surgical procedures.
The design of the system under evaluation (Sonablatern, Focal Surgery Inc., Milpitas, CA) takes advantage of new, highly efficient transducer ceramics and optimized matching layer techniques, such that both ultrasound imaging and HlFU are provided by a single transducer within a transrectal probe. Following extensive research on the ultrasound absorption properties of rectal wall and prostate tissue (and energy level requirements for lesion production), a prototype system was designed to accommodate the necessary safety factors required for transrectal therapy. Subsequently, a formal animal study was conducted, which validated the system's safety for transrectal application of HlFU energy and demonstrated its ability to ablate canine prostatic tissue [2] . Based upon the success of the animal study, a clinical protocol was devised to evaluate the safety and clinical effectiveness in humans. 
MATERIALS AND METHODS

RESULTS
Temperature levels in the canine prostate in the proximity of the focal zone reached 64°C.
This was computed by back extrapolating the temperature decay curve in Figure 3 . However, it is possible that the tissue temperature could have been underestimated if the thermocouple had not been located precisely in the focal plane. All rectal wall temperature increases recorded during these experiments remained below 5" C.
Analysis of the thermometry data from all patients demonstrated that no sustained periprostatic temperature rise exceeding 3" C occurred during a standard course of therapy. In one patient with a prostate less than 25 mm in A-P dimension, a transient rise of 17" C was recorded (Figure 4 ). This rise in temperature lasted less than 4 seconds, indicating that its cause was due t o ultrasound/heat conduction by the metallic needle.
As a group, the patients showed a statistically significant improvement in urinary flow rate and symptom scores. It should be noted that although improvements were observed in the majority of patients, the benefit was not universal. A randomized multi-center clinical trial is currently underway to determine the factors which may be most predictive of clinical success. 
CONCLUSION
This study demonstrates that discrete prostatic lesions can be produced using HlFU without significantly raising the temperature of surrounding tissue. In humans, this has resulted in clinical relief from the symptoms of BPH for a majority of the fifteen patients treated to date. This study is encouraging as it shows progress toward integrating ultrasound imaging with HlFU for a unique noninvasive approach to treatment of neoplastic disease. Further research into the interactions of ultrasound with various tissues are likely to increase the accuracy and reliability of this technique for wide range of applications.
